BainbridgeJW, SmithAJ, BarkerSS, et al.Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med, 2008; 358:2231–2239.
2.
Gonzalez-CorderoA, WestEL, PearsonRA, et al.Photoreceptor precursors derived from three-dimensional embryonic stem cell cultures integrate and mature within adult degenerate retina. Nat Biotechnol, 2013; 31:741–747.
3.
Hacein-Bey-AbinaS, PaiSY, GasparHB, et al.A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med, 2014; 371:1407–1417.
4.
HoweSJ, MansourMR, SchwarzwaelderK, et al.Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest, 2008; 118:3143–3150.
5.
GasparHB, CoorayS, GilmourKC, et al.Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med, 2011; 3:97ra80.
6.
GasparHB, ParsleyKL, HoweS, et al.Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet, 2004; 364:2181–2187.
7.
NathwaniAC, RosalesC, McIntoshJ, et al.Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther, 2011; 19:876–885.
8.
WardNJ, BuckleySM, WaddingtonSN, et al.Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood, 2011; 117:798–807.
9.
McIntoshJ, LentingPJ, RosalesC, et al.Therapeutic levels of FVIII following a single peripheral vein administration of raav vector encoding a novel human factor VIII variant. Blood, 2013; 121:3335–3344.
10.
NathwaniAC, ReissUM, TuddenhamEG, et al.Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med, 2014; 371:1994–2004.
11.
ScottLJ. Alipogene tiparvovec: A review of its use in adults with familial lipoprotein lipase deficiency. Drugs, 2015; 75:175–182.
12.
FerreiraV, PetryH, SalmonF. Immune responses to AAV-vectors, the Glybera example from bench to bedside. Front Immunol, 2014; 5:82.
13.
BryantLM, ChristopherDM, GilesAR, et al.Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev, 2013; 24:55–64.
